$15.86
7.27% yesterday
Nasdaq, Sep 23, 10:00 pm CET
ISIN
US34962G1094
Symbol
FBRX

Forte Biosciences Inc Stock price

$15.86
+4.55 40.17% 1M
+9.54 150.95% 6M
-6.85 30.16% YTD
+8.83 125.44% 1Y
-10.64 40.15% 3Y
-1,147.14 98.64% 5Y
-4,652.89 99.66% 10Y
-4,652.89 99.66% 20Y
Nasdaq, Closing price Tue, Sep 23 2025
+1.08 7.27%
ISIN
US34962G1094
Symbol
FBRX
Industry

Key metrics

Basic
Market capitalization
$197.2m
Enterprise Value
$91.1m
Net debt
positive
Cash
$106.1m
Shares outstanding
12.3m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
2.0
Financial Health
Equity Ratio
85.3%
Return on Equity
-66.7%
ROCE
-44.3%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-43.6m | -
EBIT
$-43.7m | $-57.1m
Net Income
$-42.5m | $-53.8m
Free Cash Flow
$-38.3m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-16.8% | -
EBIT
-16.8% | -54.4%
Net Income
-17.1% | -53.6%
Free Cash Flow
-22.9%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-3.6
FCF per Share
$-3.1
Short interest
0.9%
Employees
14
Rev per Employee
$0.0
Show more

Is Forte Biosciences Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,013 stocks worldwide.

Forte Biosciences Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Forte Biosciences Inc forecast:

9x Buy
90%
1x Hold
10%

Analyst Opinions

10 Analysts have issued a Forte Biosciences Inc forecast:

Buy
90%
Hold
10%

Financial data from Forte Biosciences Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 11 11
34% 34%
-
- Research and Development Expense 32 32
62% 62%
-
-44 -44
17% 17%
-
- Depreciation and Amortization 0.05 0.05
67% 67%
-
EBIT (Operating Income) EBIT -44 -44
17% 17%
-
Net Profit -42 -42
17% 17%
-

In millions USD.

Don't miss a Thing! We will send you all news about Forte Biosciences Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Forte Biosciences Inc Stock News

Neutral
Business Wire
9 days ago
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, announced additional details from the oral presentation “FB102 prevents histological damage and mitigates gluten challenge-induced symptoms in a celiac disease phase 1b study - Jason Tye-Din, Walter and Eliza Hall...
Neutral
Business Wire
about one month ago
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced its second quarter 2025 financial results and provided a business update. “I am deeply appreciative of the Forte team's incredible accomplishments in initiating 3 clinical trials for FB102 with dat...
Neutral
Business Wire
3 months ago
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (Nasdaq: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced the pricing of a public offering of 5,630,450 shares of its common stock at a price to the public of $12.00 per share and, in lieu of common stock to certain investors who so chose, pre-funded warrants to purchase up t...
More Forte Biosciences Inc News

Company Profile

Forte Biosciences, Inc. engages in the development of biopharmaceutical products. It is a clinical stage dermatology company focuses in the treatment of inflammatory skin diseases. It offers FB-401, a live bio-therapeutic product. The company was founded by Paul A. Wagner in 2017 and is headquartered in Torrance, CA.

Head office United States
CEO Paul Wagner
Employees 14
Founded 2017
Website www.fortebiorx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today